XenaCare Holdings becomes national sponsor of Arthritis Foundation

XenaCare Holdings, Inc. (OTCBB: XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that is has become a national sponsor of the Arthritis Foundation at the National Proud Sponsor level.

“As one of the largest and most well-respected nonprofit organizations dedicated to arthritis research and public health education, the Arthritis Foundation is on an important mission to improve the quality of life for millions of people around the world suffering from more than 100 different types of arthritis,” explained Frank Rizzo, President of XenaCare Holdings. “We are honored to be associated with the Arthritis Foundation as a national sponsor and we look forward to continuing to work closely with the Organization to help support their ongoing efforts,” he added.

With the sponsorship of the Arthritis Foundation, Cobroxin may bear the Arthritis Foundation Proud Sponsor Logo on its packaging. This logo illustrates to consumers that Cobroxin is proud to support the Arthritis Foundation's efforts to help people take control of arthritis. Additionally, the Arthritis Foundation will work with XenaCare and other Proud Sponsors to help build awareness about Cobroxin through its magazine, Arthritis Today, its membership e-newsletter and on its website, Arthritis.org.

The National Proud Sponsor program represents the highest level of collaboration with the Arthritis Foundation. According to the Arthritis Foundation, Proud Sponsors provide critical support of the Foundation's key mission areas including:

• Advocacy - Local, state and national efforts to advance vital legislation.
• Research - Cutting edge, peer-reviewed research that has the greatest potential for advancement in the search for a cure.
• Public health - Information and empowering programs and services.
• Community-based outreach - Network of 42 chapter offices

Additional National Proud Sponsors include Wyeth, Abbott, Nature Made® TripleFlex™, Genentech, Bristol-Myers Squibb and Osteo Bi-Flex.

In 2009, XenaCare received the exclusive license from biotechnology company, Nutra Pharma Corporation (OTCBB: NPHC), to market and distribute Cobroxin throughout the United States. Cobroxin is clinically proven to treat moderate to severe (Stage 2) chronic pain and is currently available for sale at several retailers, including online at Cobroxin.com.